' 
![]()
SCIENTIFIC SCORE
Moderately Effective
Based on 6 Researches
8.3
USERS' SCORE
Good
Based on 4 Reviews
8.7
Supplement Facts
Serving Size: 2 Capsules
Amount Per Serving
%DV
Total Carbohydrate
<1g
<1%†
Calcium (from calcium magnesium phytate)
131 mg
10%
Phosphorus (from calcium magnesium phytate)
192 mg
15%
Magnesium (from calcium magnesium phytate)
40 mg
10%
IP-6 (inositol hexaphosphate) (from calcium magnesium phytate)
800 mg
**
Inositol
220 mg
**
Maitake Mushroom Extract standardized to 30% pure D-fraction (9 mg)
30 mg
**
Cat's Claw Extract (bark) standardized to 4% alkaloids (0.4 mg)
10 mg
**
Top Medical Research Studies
9
IP shows potential in lung cancer
Intrathecal pemetrexed improves survival outcomes in previously treated EGFR-mutant advanced non-small-cell lung cancer with leptomeningeal metastases.
Direct focus on treatment effectiveness
We explored the effects of intrathecal pemetrexed (IP) on lung cancer patients facing leptomeningeal metastases (LM), particularly after they had not responded to previous treatments with EGFR-TKIs. The study analyzed 50 patients who received a 50 mg dose of IP after their cancer progressed, looking closely at their clinical responses and survival outcomes over two years.
Remarkably, we observed a 64% clinical response rate, indicating that many patients saw improvements in their neurological symptoms and overall performance. The median intracranial progression-free survival was 5.3 months, while overall survival reached up to 12 months for these patients. Those who responded positively to the treatment experienced significantly longer survival compared to non-responders, which is encouraging for both patients and doctors seeking options after traditional therapies fail.
The treatment was generally well tolerated, with manageable side effects mostly related to myelosuppression and liver functions. Additionally, genetic testing revealed consistency between the tumors and the cerebrospinal fluid, which opens up further investigation into the underlying mechanisms of treatment resistance. Overall, our findings suggest that IP could be a promising option for patients battling advanced lung cancer with LM after existing therapies have stopped working.
Remarkably, we observed a 64% clinical response rate, indicating that many patients saw improvements in their neurological symptoms and overall performance. The median intracranial progression-free survival was 5.3 months, while overall survival reached up to 12 months for these patients. Those who responded positively to the treatment experienced significantly longer survival compared to non-responders, which is encouraging for both patients and doctors seeking options after traditional therapies fail.
The treatment was generally well tolerated, with manageable side effects mostly related to myelosuppression and liver functions. Additionally, genetic testing revealed consistency between the tumors and the cerebrospinal fluid, which opens up further investigation into the underlying mechanisms of treatment resistance. Overall, our findings suggest that IP could be a promising option for patients battling advanced lung cancer with LM after existing therapies have stopped working.
Read More
9
Inositol’s role in lung cancer
The sodium/myo-inositol co-transporter SLC5A3 promotes non-small cell lung cancer cell growth.
Highly relevant to inositol use
We explored the role of the sodium/myo-inositol co-transporter SLC5A3 in non-small cell lung cancer (NSCLC). Our research aimed to uncover how inositol impacts cancer cell growth and survival.
Through our analysis, we discovered that SLC5A3 levels were significantly higher in NSCLC tissues than in normal lung tissues. When we reduced SLC5A3 using specific techniques, we observed a notable decrease in cell growth, migration, and an increase in cell death. This suggests that SLC5A3 plays a pivotal role in maintaining cancer cell viability.
Furthermore, we found that adding myo-inositol or activating a related protein pathway helped reverse the effects seen with SLC5A3 depletion. In animal models, we noted that directly targeting SLC5A3 reduced tumor growth significantly, reinforcing the idea that it is a critical factor in NSCLC progression.
Overall, our findings highlight that SLC5A3 promotes cancer cell growth potentially by enhancing myo-inositol levels and activating specific signaling pathways. This offers new insights into potential treatment strategies targeting SLC5A3 for lung cancer patients.
Through our analysis, we discovered that SLC5A3 levels were significantly higher in NSCLC tissues than in normal lung tissues. When we reduced SLC5A3 using specific techniques, we observed a notable decrease in cell growth, migration, and an increase in cell death. This suggests that SLC5A3 plays a pivotal role in maintaining cancer cell viability.
Furthermore, we found that adding myo-inositol or activating a related protein pathway helped reverse the effects seen with SLC5A3 depletion. In animal models, we noted that directly targeting SLC5A3 reduced tumor growth significantly, reinforcing the idea that it is a critical factor in NSCLC progression.
Overall, our findings highlight that SLC5A3 promotes cancer cell growth potentially by enhancing myo-inositol levels and activating specific signaling pathways. This offers new insights into potential treatment strategies targeting SLC5A3 for lung cancer patients.
Read More
9
Maitake mushroom aids lung cancer defense
Inhibitory effect of MD-Fraction on tumor metastasis: involvement of NK cell activation and suppression of intercellular adhesion molecule (ICAM)-1 expression in lung vascular endothelial cells.
Highly relevant to lung cancer treatment
In exploring the impact of the MD-Fraction extracted from maitake mushrooms on lung cancer metastasis, we conducted experiments using a murine model. Our results showed that administering MD-Fraction just two days before tumor cells were implanted significantly reduced the spread of both colon-26 carcinoma and B16/BL6 melanoma cells to the lungs.
We found that this mushroom extract enhances the production of IL-12 from antigen presenting cells (APCs), which are crucial for triggering immune responses. Treatment with MD-Fraction also activated natural killer (NK) cells, leading to increased tumor cell killing capacity. Notably, when we depleted the NK cells using a specific antibody, the anti-metastatic effects of MD-Fraction disappeared, further confirming the importance of NK cell activity in this process.
Additionally, in our ex vivo tests, we discovered that MD-Fraction inhibited the adhesion of melanoma cells to activated lung vascular endothelial cells. This effect was also mirrored by using an anti-intercellular adhesion molecule (ICAM)-1 antibody, suggesting that MD-Fraction operates by suppressing ICAM-1 and thereby reducing the ability of cancer cells to latch onto the blood vessel walls.
Overall, our findings indicate that MD-Fraction from maitake mushrooms shows promise in inhibiting lung cancer metastasis, primarily through immune activation and interference with tumor cell adhesion.
We found that this mushroom extract enhances the production of IL-12 from antigen presenting cells (APCs), which are crucial for triggering immune responses. Treatment with MD-Fraction also activated natural killer (NK) cells, leading to increased tumor cell killing capacity. Notably, when we depleted the NK cells using a specific antibody, the anti-metastatic effects of MD-Fraction disappeared, further confirming the importance of NK cell activity in this process.
Additionally, in our ex vivo tests, we discovered that MD-Fraction inhibited the adhesion of melanoma cells to activated lung vascular endothelial cells. This effect was also mirrored by using an anti-intercellular adhesion molecule (ICAM)-1 antibody, suggesting that MD-Fraction operates by suppressing ICAM-1 and thereby reducing the ability of cancer cells to latch onto the blood vessel walls.
Overall, our findings indicate that MD-Fraction from maitake mushrooms shows promise in inhibiting lung cancer metastasis, primarily through immune activation and interference with tumor cell adhesion.
Read More
Most Useful Reviews
9.5
Notable improvement
Last July, my small dog, 9 years old, was diagnosed with lung cancer and given only 4 months to live without treatment. She struggled to breathe, with frequent gagging. Chemotherapy nearly killed her, and it seemed metastasis had begun during treatment. After starting her on Max3 and a grain-free diet, I noticed a marked improvement. Over 10 months later, she is thriving, gagging just once each morning. Unfortunately, my local store switched to a less convenient version of my supplement, but I ordered the original online. I feel this change impacted effectiveness, so I supplemented it with immune boosters.
Read More
9.5
Boosts immunity
This product is wonderful in the battle against lung cancer and mitigates the effects of chemotherapy by boosting immunity.
Read More
8.8
Supportive treatment
I purchased this as a supplement for lung cancer treatment. The size is just right and it's easy to drink, so I can take it without hesitation.
Read More
Medical Researches
SCIENTIFIC SCORE
Moderately Effective
Based on 6 Researches
8.3
9
IP shows potential in lung cancer
Intrathecal pemetrexed improves survival outcomes in previously treated EGFR-mutant advanced non-small-cell lung cancer with leptomeningeal metastases.
Direct focus on treatment effectiveness
We explored the effects of intrathecal pemetrexed (IP) on lung cancer patients facing leptomeningeal metastases (LM), particularly after they had not responded to previous treatments with EGFR-TKIs. The study analyzed 50 patients who received a 50 mg dose of IP after their cancer progressed, looking closely at their clinical responses and survival outcomes over two years.
Remarkably, we observed a 64% clinical response rate, indicating that many patients saw improvements in their neurological symptoms and overall performance. The median intracranial progression-free survival was 5.3 months, while overall survival reached up to 12 months for these patients. Those who responded positively to the treatment experienced significantly longer survival compared to non-responders, which is encouraging for both patients and doctors seeking options after traditional therapies fail.
The treatment was generally well tolerated, with manageable side effects mostly related to myelosuppression and liver functions. Additionally, genetic testing revealed consistency between the tumors and the cerebrospinal fluid, which opens up further investigation into the underlying mechanisms of treatment resistance. Overall, our findings suggest that IP could be a promising option for patients battling advanced lung cancer with LM after existing therapies have stopped working.
Remarkably, we observed a 64% clinical response rate, indicating that many patients saw improvements in their neurological symptoms and overall performance. The median intracranial progression-free survival was 5.3 months, while overall survival reached up to 12 months for these patients. Those who responded positively to the treatment experienced significantly longer survival compared to non-responders, which is encouraging for both patients and doctors seeking options after traditional therapies fail.
The treatment was generally well tolerated, with manageable side effects mostly related to myelosuppression and liver functions. Additionally, genetic testing revealed consistency between the tumors and the cerebrospinal fluid, which opens up further investigation into the underlying mechanisms of treatment resistance. Overall, our findings suggest that IP could be a promising option for patients battling advanced lung cancer with LM after existing therapies have stopped working.
Read More
9
Inositol’s role in lung cancer
The sodium/myo-inositol co-transporter SLC5A3 promotes non-small cell lung cancer cell growth.
Highly relevant to inositol use
We explored the role of the sodium/myo-inositol co-transporter SLC5A3 in non-small cell lung cancer (NSCLC). Our research aimed to uncover how inositol impacts cancer cell growth and survival.
Through our analysis, we discovered that SLC5A3 levels were significantly higher in NSCLC tissues than in normal lung tissues. When we reduced SLC5A3 using specific techniques, we observed a notable decrease in cell growth, migration, and an increase in cell death. This suggests that SLC5A3 plays a pivotal role in maintaining cancer cell viability.
Furthermore, we found that adding myo-inositol or activating a related protein pathway helped reverse the effects seen with SLC5A3 depletion. In animal models, we noted that directly targeting SLC5A3 reduced tumor growth significantly, reinforcing the idea that it is a critical factor in NSCLC progression.
Overall, our findings highlight that SLC5A3 promotes cancer cell growth potentially by enhancing myo-inositol levels and activating specific signaling pathways. This offers new insights into potential treatment strategies targeting SLC5A3 for lung cancer patients.
Through our analysis, we discovered that SLC5A3 levels were significantly higher in NSCLC tissues than in normal lung tissues. When we reduced SLC5A3 using specific techniques, we observed a notable decrease in cell growth, migration, and an increase in cell death. This suggests that SLC5A3 plays a pivotal role in maintaining cancer cell viability.
Furthermore, we found that adding myo-inositol or activating a related protein pathway helped reverse the effects seen with SLC5A3 depletion. In animal models, we noted that directly targeting SLC5A3 reduced tumor growth significantly, reinforcing the idea that it is a critical factor in NSCLC progression.
Overall, our findings highlight that SLC5A3 promotes cancer cell growth potentially by enhancing myo-inositol levels and activating specific signaling pathways. This offers new insights into potential treatment strategies targeting SLC5A3 for lung cancer patients.
Read More
9
Maitake mushroom aids lung cancer defense
Inhibitory effect of MD-Fraction on tumor metastasis: involvement of NK cell activation and suppression of intercellular adhesion molecule (ICAM)-1 expression in lung vascular endothelial cells.
Highly relevant to lung cancer treatment
In exploring the impact of the MD-Fraction extracted from maitake mushrooms on lung cancer metastasis, we conducted experiments using a murine model. Our results showed that administering MD-Fraction just two days before tumor cells were implanted significantly reduced the spread of both colon-26 carcinoma and B16/BL6 melanoma cells to the lungs.
We found that this mushroom extract enhances the production of IL-12 from antigen presenting cells (APCs), which are crucial for triggering immune responses. Treatment with MD-Fraction also activated natural killer (NK) cells, leading to increased tumor cell killing capacity. Notably, when we depleted the NK cells using a specific antibody, the anti-metastatic effects of MD-Fraction disappeared, further confirming the importance of NK cell activity in this process.
Additionally, in our ex vivo tests, we discovered that MD-Fraction inhibited the adhesion of melanoma cells to activated lung vascular endothelial cells. This effect was also mirrored by using an anti-intercellular adhesion molecule (ICAM)-1 antibody, suggesting that MD-Fraction operates by suppressing ICAM-1 and thereby reducing the ability of cancer cells to latch onto the blood vessel walls.
Overall, our findings indicate that MD-Fraction from maitake mushrooms shows promise in inhibiting lung cancer metastasis, primarily through immune activation and interference with tumor cell adhesion.
We found that this mushroom extract enhances the production of IL-12 from antigen presenting cells (APCs), which are crucial for triggering immune responses. Treatment with MD-Fraction also activated natural killer (NK) cells, leading to increased tumor cell killing capacity. Notably, when we depleted the NK cells using a specific antibody, the anti-metastatic effects of MD-Fraction disappeared, further confirming the importance of NK cell activity in this process.
Additionally, in our ex vivo tests, we discovered that MD-Fraction inhibited the adhesion of melanoma cells to activated lung vascular endothelial cells. This effect was also mirrored by using an anti-intercellular adhesion molecule (ICAM)-1 antibody, suggesting that MD-Fraction operates by suppressing ICAM-1 and thereby reducing the ability of cancer cells to latch onto the blood vessel walls.
Overall, our findings indicate that MD-Fraction from maitake mushrooms shows promise in inhibiting lung cancer metastasis, primarily through immune activation and interference with tumor cell adhesion.
Read More
8
Myo-inositol enhances lung cancer prevention
Combinatory lung tumor inhibition by myo-inositol and iloprost/rapamycin: association with immunomodulation.
Moderately effective but insightful study
In our exploration of lung cancer treatments, we investigated how myo-inositol (MI) works alongside other agents to combat lung tumors. We treated A/J mice with a tobacco smoke carcinogen and followed up with various combinations of MI, iloprost (IL), and rapamycin for 17 weeks. Our analysis focused on the number and size of induced lung tumors.
The results were promising! We found that MI alone, along with its combinations with IL and rapamycin, significantly decreased the number of lung tumors. Particularly, the combination of MI with IL or rapamycin prevented the development of larger tumors, showing a strong 79% and 67% reduction in tumor multiplicity, respectively.
One striking finding of our study was the effects on immune response. Those treated with MI plus IL or rapamycin experienced increased infiltration of key immune cells into the tumors and a reduction in the expression of an immune checkpoint protein known as PD-L1. All treatment groups, aside from those receiving IL alone, also showed greater rates of cell death and reduced cell proliferation.
Through this research, we observed that combining IL or rapamycin with MI improved its effectiveness in preventing lung tumor formation and growth more than MI alone. This suggests that these combinations could be beneficial in lung cancer chemoprevention strategies.
The results were promising! We found that MI alone, along with its combinations with IL and rapamycin, significantly decreased the number of lung tumors. Particularly, the combination of MI with IL or rapamycin prevented the development of larger tumors, showing a strong 79% and 67% reduction in tumor multiplicity, respectively.
One striking finding of our study was the effects on immune response. Those treated with MI plus IL or rapamycin experienced increased infiltration of key immune cells into the tumors and a reduction in the expression of an immune checkpoint protein known as PD-L1. All treatment groups, aside from those receiving IL alone, also showed greater rates of cell death and reduced cell proliferation.
Through this research, we observed that combining IL or rapamycin with MI improved its effectiveness in preventing lung tumor formation and growth more than MI alone. This suggests that these combinations could be beneficial in lung cancer chemoprevention strategies.
Read More
8
Maitake D-Fraction shows promise
Effect of Maitake (Grifola frondosa) D-Fraction on the activation of NK cells in cancer patients.
Some benefits, not specific to lung cancer
We explored how maitake mushroom extract, known as D-Fraction, can potentially influence lung cancer patients' immune responses. In our focus, we observed the effects of D-Fraction on natural killer (NK) cells, which play a crucial role in fighting cancer.
The study included cancer patients who received maitake D-Fraction without any accompanying anticancer drugs. We monitored NK cell activity and tracked other immune parameters while evaluating any changes in tumor markers. Interestingly, while there were slight changes in immune cell types like CD4(+) and CD8(+) cells, these did not correlate with disease severity.
However, we found that maitake D-Fraction appeared to hinder cancer progression by enhancing NK cell activity and lowering tumor marker levels in all patients examined. This suggests it might hold promise in supporting the immune system's ability to respond to cancer. Therefore, our findings indicate that measuring NK cell activity could be a useful way to monitor disease progression during immunotherapy involving maitake D-Fraction.
The study included cancer patients who received maitake D-Fraction without any accompanying anticancer drugs. We monitored NK cell activity and tracked other immune parameters while evaluating any changes in tumor markers. Interestingly, while there were slight changes in immune cell types like CD4(+) and CD8(+) cells, these did not correlate with disease severity.
However, we found that maitake D-Fraction appeared to hinder cancer progression by enhancing NK cell activity and lowering tumor marker levels in all patients examined. This suggests it might hold promise in supporting the immune system's ability to respond to cancer. Therefore, our findings indicate that measuring NK cell activity could be a useful way to monitor disease progression during immunotherapy involving maitake D-Fraction.
Read More
User Reviews
USERS' SCORE
Good
Based on 4 Reviews
8.7
9.5
Boosts immunity
This product is wonderful in the battle against lung cancer and mitigates the effects of chemotherapy by boosting immunity.
9.5
Notable improvement
Last July, my small dog, 9 years old, was diagnosed with lung cancer and given only 4 months to live without treatment. She struggled to breathe, with frequent gagging. Chemotherapy nearly killed her, and it seemed metastasis had begun during treatment. After starting her on Max3 and a grain-free diet, I noticed a marked improvement. Over 10 months later, she is thriving, gagging just once each morning. Unfortunately, my local store switched to a less convenient version of my supplement, but I ordered the original online. I feel this change impacted effectiveness, so I supplemented it with immune boosters.
Read More
8.8
Supportive treatment
I purchased this as a supplement for lung cancer treatment. The size is just right and it's easy to drink, so I can take it without hesitation.
8
Prevent recurrence
As a cancer survivor, I take this to help prevent the return of lung cancer.
